Cramer says the $8.3 billion bid signifies that big pharmaceutical companies are thinking big even as Roche calls this a "bolt-on" acquisition. Cramer notes in the old days, "bolt on" would have meant anything less than $1 billion.
Cramer calls this deal important because so many biotech companies are losing money the way InterMune was before it had a breakthrough. His game plan is for a prospective buyer to find a biotech company in stage three, which means it is about to get FDA approval, and looks like it is a need that is unmet.ITMN data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.